414 Views

Plenary

Session: Plenary Session 1: Real Time Use of Real-World Data for Decision-Making

Real Time Use of Real-World Data for Decision-Making

Monday, April 24, 2023

9:15 AM – 11:00 AM GMT

Moderator(s)

Larus S. Gudmundsson (he/him/his)

Associate Professor
University of Iceland
Reykjavik, Iceland
Almut G. Winterstein, PhD, FISPE

Distinguished Professor
University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety
Gainesville, Florida, United States

Speaker(s)

Martin Ingi I. Sigurdsson, MD, PhD (he/him/his)

Professor, University of Iceland; Chief Physician, Landspitali University Hospital.
Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland., United States
Guðrún Aspelund (she/her/hers)

Chief Epidemiologist
Directorate of Health Iceland
Reykjavík, Iceland
Menno van der Elst (he/him/his)

Member
Dutch Medicines ‎Evaluation Board‎

Disclosure(s):

Larus Gudmundsson: No financial relationships to disclose

Almut G. Winterstein, PhD: No relevant disclosure to display

Martin Ingi I. Sigurdsson, MD, PhD: No financial relationships to disclose

Guðrún Aspelund: No financial relationships to disclose

Menno van der Elst: No financial relationships to disclose

The COVID-19 pandemic triggered an unprecedent push towards high need for generation and use of real world data to support timely decisions. This session will provide insights into clinical and policy drive decision making at the national and international level.

9:15-9:45: Disseminating COVID-19 science: the Iceland experience
Martin Ingi Sigurdsson, Professor of Anesthesiology and Critical Care Medicine, University of Iceland

9:45-10:15: Contact Tracing in COVID-19: Data and Digitization
Guðrún Aspelund, Chief Epidemiologist, Icelandic Directorate of Health

10:15-10:45: Value of real world data for decision making at the European level
Menno van der Elst, EMA Pharmacovigilance Risk Assessment Commitee (PRAC) member, Dutch Medicines Evaluation Board

10:45-11:00: Discussion